{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:58Z","timestamp":1791357538030,"version":"4.3.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D) trial demonstrated noninferiority of intravenous ketamine vs ECT for nonpsychotic TRD. Clinical features that can guide selection of ketamine vs ECT may inform shared decision-making for patients with TRD.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether selected clinical features were associated with differential improvement with ketamine vs ECT.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This secondary analysis of an open-label noninferiority randomized clinical trial was a multicenter study conducted at 5 US academic medical centers from April 7, 2017, to November 11, 2022. Analyses for this study, which were not prespecified in the trial protocol, were conducted from May 10 to Oct 31, 2023. The study cohort included patients with TRD, aged 21 to 75 years, who were in a current nonpsychotic depressive episode of at least moderate severity and were referred for ECT by their clinicians.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Eligible participants were randomized 1:1 to receive either 6 infusions of ketamine or 9 treatments with ECT over 3 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Association between baseline factors (including 16-item Quick Inventory of Depressive Symptomatology Self-Report [QIDS-SR16], Montgomery-Asberg Depression Rating Scale [MADRS], premorbid intelligence, cognitive function, history of attempted suicide, and inpatient vs outpatient status) and treatment response were assessed with repeated measures mixed-effects model analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 365 participants included in this study (mean [SD] age, 46.0 [14.5] years; 191 [52.3%] female), 195 were randomized to the ketamine group and 170 to the ECT group. In repeated measures mixed-effects models using depression levels over 3 weeks and after false discovery rate adjustment, participants with a baseline QIDS-SR16\u2009score of 20 or less (\u22127.7 vs \u22125.6 points) and those starting treatment as outpatients (\u22128.4 vs \u22126.2 points) reported greater reduction in the QIDS-SR16 with ketamine vs ECT. Conversely, those with a baseline QIDS-SR16 score of more than 20 (ie, very severe depression) and starting treatment as inpatients reported greater reduction in the QIDS-SR16 earlier in course of treatment (\u22128.4 vs \u22126.7 points) with ECT, but scores were similar in both groups at the end-of-treatment visit (\u22129.0 vs \u22129.9 points). In the ECT group only, participants with higher scores on measures of premorbid intelligence (\u221214.0 vs \u221211.2 points) and with a comorbid posttraumatic stress disorder diagnosis (\u221216.6 vs \u221212.0 points) reported greater reduction in the MADRS score. Those with impaired memory recall had greater reduction in MADRS during the second week of treatment (\u221213.4 vs \u22129.6 points), but the levels of MADRS were similar to those with unimpaired recall at the end-of-treatment visit (\u221214.3 vs \u221212.2 points). Other results were not significant after false discovery rate adjustment.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this secondary analysis of the ELEKT-D randomized clinical trial of ECT vs ketamine, greater improvement in depression was observed with intravenous ketamine among outpatients with nonpsychotic TRD who had moderately severe or severe depression, suggesting that these patients may consider ketamine over ECT for TRD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.17786","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:04:24Z","timestamp":1719327864000},"page":"e2417786","source":"Crossref","is-referenced-by-count":30,"title":["Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression"],"prefix":"10.1001","volume":"7","author":[{"given":"Manish Kumar","family":"Jha","sequence":"first","affiliation":[{"name":"Center for Depression Research and Clinical Care, Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas"},{"name":"Peter O\u2019Donnell Jr Brain Institute, The University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Collins","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murrough","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Goes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Altinay","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Aloysi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Asghar-Ali","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas"},{"name":"Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas"},{"name":"The Menninger Clinic, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Barnett","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Costi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Psychopharmacology and Emotion Research Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Nikayin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"C5Research, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ostroff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Reti","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"C5Research, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay J.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas"},{"name":"Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas"},{"name":"The Menninger Clinic, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"11","key":"zoi240581r1","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi240581r2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States.","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi240581r3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study.","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi240581r4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","article-title":"Electroconvulsive therapy.","volume":"386","author":"Espinoza","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi240581r5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamapsychiatry.2017.1670","article-title":"Modern electroconvulsive therapy: vastly improved yet greatly underused.","volume":"74","author":"Sackeim","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi240581r6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"An update on community ketamine practices.","volume":"179","author":"O\u2019Brien","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"7","key":"zoi240581r7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders.","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi240581r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression\u2014first FDA-approved antidepressant in a new class.","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi240581r9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cct.2018.12.009","article-title":"Electroconvulsive therapy (ECT) vs. ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol.","volume":"77","author":"Mathew","year":"2019","journal-title":"Contemp Clin Trials"},{"issue":"25","key":"zoi240581r10","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression.","volume":"388","author":"Anand","year":"2023","journal-title":"N Engl J Med"},{"key":"zoi240581r11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"5","key":"zoi240581r12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"6","key":"zoi240581r13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.biopsych.2005.08.022","article-title":"An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.","volume":"59","author":"Rush","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"8","key":"zoi240581r14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1076\/jcen.24.8.1123.8375","article-title":"North American Adult Reading Test: age norms, reliability, and validity.","volume":"24","author":"Uttl","year":"2002","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"zoi240581r15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","article-title":"Hopkins Verbal Learning Test\u2013Revised: normative data and analysis of inter-form and test-retest reliability.","volume":"12","author":"Benedict","year":"1998","journal-title":"Clin Neuropsychol"},{"key":"zoi240581r16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jad.2020.05.101","article-title":"Predictors of cognitive impairment in treatment-resistant depression.","volume":"274","author":"Gregory","year":"2020","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi240581r17","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14491","article-title":"Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID Intravenous Ketamine Study.","volume":"84","author":"Feeney","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi240581r18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder.","volume":"15","author":"Rong","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"zoi240581r19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ijnp\/pyac070","article-title":"Predictors of electroconvulsive therapy outcome in major depressive disorder.","volume":"26","author":"Su","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"zoi240581r20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/sj.npp.1301180","article-title":"The cognitive effects of electroconvulsive therapy in community settings.","volume":"32","author":"Sackeim","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"zoi240581r21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.","volume":"35","author":"Frye","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"zoi240581r22","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.4088\/JCP.16l11277","article-title":"The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use.","volume":"78","author":"Albott","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"zoi240581r23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/0004867415590631","article-title":"Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.","volume":"49","author":"Ford","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"issue":"12","key":"zoi240581r24","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","article-title":"International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators.","volume":"27","author":"Price","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1-3","key":"zoi240581r25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2006.03.024","article-title":"Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS.","volume":"95","author":"Carmody","year":"2006","journal-title":"J Affect Disord"},{"key":"zoi240581r26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-244X-12-115","article-title":"Predictors of the short-term responder rate of electroconvulsive therapy in depressive disorders\u2014a population based study.","volume":"12","author":"Nordenskj\u00f6ld","year":"2012","journal-title":"BMC Psychiatry"},{"key":"zoi240581r27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jad.2020.11.059","article-title":"The association of body mass index (BMI) with treatment outcomes in patients with major depressive disorder.","volume":"281","author":"Xiao","year":"2021","journal-title":"J Affect Disord"},{"key":"zoi240581r28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jad.2021.03.032","article-title":"Is obesity a determinant of success with pharmacological treatment for depression? a systematic review, meta-analysis and meta-regression.","volume":"287","author":"Grigolon","year":"2021","journal-title":"J Affect Disord"},{"key":"zoi240581r29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jad.2023.05.042","article-title":"Body mass index and clinical outcomes in individuals with major depressive disorder: findings from the GSRD European Multicenter Database.","volume":"335","author":"Kraus","year":"2023","journal-title":"J Affect Disord"},{"key":"zoi240581r30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jad.2020.01.113","article-title":"Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder.","volume":"267","author":"Puzhko","year":"2020","journal-title":"J Affect Disord"},{"key":"zoi240581r31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jad.2018.02.089","article-title":"Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: findings from CO-MED trial.","volume":"234","author":"Jha","year":"2018","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi240581r32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2215-0366(15)00579-9","article-title":"Precision psychiatry: a neural circuit taxonomy for depression and anxiety.","volume":"3","author":"Williams","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"zoi240581r33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamapsychiatry.2023.3979","article-title":"Choosing between ketamine and electroconvulsive therapy for outpatients with treatment-resistant depression-advantage ketamine?","volume":"80","author":"Mathew","year":"2023","journal-title":"JAMA Psychiatry"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820305\/jha_2024_oi_240581_1718225904.99538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:04:26Z","timestamp":1719327866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820305"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17786","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}